Business
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
MOUNTAIN VIEW, Calif., June 03, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally def
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/442f6a6d0ee11d1c7bc7f0f4a7eb71cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LvFv.hYCR.LtkcD6iU31rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/442f6a6d0ee11d1c7bc7f0f4a7eb71cb","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sjA1bjAuUgGCpDSKU.28pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/442f6a6d0ee11d1c7bc7f0f4a7eb71cb","width":1200,"height":388}},"lazy":false},{"type":"text","content":"– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole –","length":194,"tagName":"p","attribs":{}},{"type":"text","content":"– Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) –","length":249,"tagName":"p","attribs":{}},{"type":"text","content":"– CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen’s d = 1.1, p<0.05) –","length":199,"tagName":"p","attribs":{}},{"type":"text","content":"– Alto expects to initiate a Phase 2b trial, designed to be a potentially pivotal study, with ALTO-207 in patients with TRD by mid-2026 and report topline data in 2027 –","length":169,"tagName":"p","attribs":{}},{"type":"text","content":"– Cash guidance unchanged; current cash is expected to fund planned operations into 2028, through at least five planned clinical study readouts –","length":145,"tagName":"p","attribs":{}},{"type":"text","content":"– Company to host conference call and webcast today, June 3, at 8 a.m. ET –","length":75,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., June 03, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development ...